drugset / Trial / NCT04556292
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
This open label, multi-centre phase II study will assess the efficacy and safety of single agent SC10914 in metastatic breast cancer patients with gBRCA 1/2 mutations.
Timeline
- Start
- 2020-08-12
- Primary completion
- 2022-03-30
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SC10914 | Unknown | 400 mg | — |